Lynch Regenerative Medicine, LLC (LRM) has successfully concluded its Series A financing to advance innovative skin rejuvenation and regeneration solutions based on FDA-approved pure platelet-derived growth factor (PDGF). Champion VC, managing assets of the Frist family of Nashville, Tennessee, led the funding round alongside Dr. Samuel Lynch, CEO and founder of LRM.
“Our focus is on delivering safe and effective PDGF-based solutions to meet the unmet needs in skincare,” remarked Dr. Lynch. “This technology has already transformed healing in orthopedic and periodontal fields, and now we’re poised to elevate skincare.”
LRM’s patented pure PDGF technology powers four FDA-approved products, enhancing tissue healing and regeneration across multiple medical disciplines for over 15 years. The company now aims to bring this proven success to skincare, starting with Ariessence™ Pure PDGF+, tailored for aesthetic clinics and dermatology practices.
“Growth factors like PDGF are pivotal in modern skincare, yet Ariessence™ stands out with its robust scientific backing,” Lynch added. “We’re excited to leverage this foundation to redefine aesthetic regenerative medicine.”
The Series A financing will bolster LRM’s commercialization efforts, including team expansion and strategic hires in commercialization, business development, clinical development, and regulatory affairs. PH Partners provided financial advisory services, and Bass, Berry & Sims served as legal counsel for the transaction.
Founded in 2023 and headquartered in Franklin, Tennessee, LRM is committed to leveraging its regenerative medicine expertise to innovate within the $100 billion aesthetics and wound-care markets.
